Figure 1.

PMNL priming parameters, namely, rate of superoxide release (a) and PMNL CD11b levels (b), before and following 1 and 2 months of either metformin (blank) or combined Roziglytazone (dotted) treatment. Data are mean ± SEM. ^aP < 0.05, vs. HC subjects; ^b P < 0.05, vs. untreated DM patients.